Immune checkpoint therapies (ICT) can reinvigorate the effector functions of anti-tumour T
cells, improving cancer patient outcomes. Anti-tumour T cells are initially formed during their …

Chemotherapy has historically been the mainstay of cancer treatment, but our
understanding of what drives a successful therapeutic response remains limited. The …

Liver cancer is the third leading cause of cancer death worldwide. Hepatocellular carcinoma
(HCC) is the most common primary malignant tumor of the liver. Liver resection or …

Over the past decade, immune-checkpoint inhibitors (ICIs) have revolutionized the treatment
of cancer. In mesothelioma, a rare cancer with a dismal prognosis generally caused by …

Inhibitors of the DNA damage signaling kinase ATR increase tumor cell killing by
chemotherapies that target DNA replication forks but also kill rapidly proliferating immune …

Head and neck squamous carcinoma (HNSCC) is highly infiltrated by immune cells,
including tumor-infiltrating lymphocytes and myeloid lineage cells. In the tumor …

Introduction Immunotherapies have shown great promise, but are not effective for all tumors
types and are effective in less than 3% of patients with pancreatic ductal adenocarcinomas …

Malignant pleural mesothelioma (MPM) is an incurable cancer with a dismal prognosis and
few effective treatment options. Nonetheless, recent positive phase III trial results for immune …

Introduction: Glioblastoma (GBM) is the most common invasive brain tumor composed of
diverse cell types with poor prognosis. The highly complex tumor microenvironment (TME) …

While chemotherapy remains the first-line treatment for many cancers, it is still unclear what
distinguishes responders from non-responders. Here, we characterize the chemotherapy …